Current state: 2026.
The regulatory text converged on ICH M10. Inspection practice diverged. The 2025 483 categories tell you where the surface friction sits today.
Current state: 2026.
What's live · what just changed · what's in transitionThe regulatory text converged on ICH M10. The inspection practice diverged. The 2025 483 categories tell you where the surface friction sits today.
ICH M10 v1.
All five major regulators (FDA, EMA, PMDA, ANVISA, WHO) accept: 4-6-15/4-6-20 · ≥75% standards within ±15% (±20% LLOQ) · ISR mandatory for BE/FIH/pivotal PK · ≥67% reanalysis within ±20% (±30% LBA).
2018 + M10 parallel.
FDA chose parallel implementation. 2018 Guidance still authoritative. January 2026 draft Q&A clarifies partial-validation reading (FDA more permissive than EMA).
Full M10 adoption.
Retired 2011 Guideline 21 Jan 2023. Nov 2023 corrigendum clarified calibration-curve back-calculation reporting gaps (top 2023 inspection finding).
Implementation 4 Dec 2024.
Aligned ICH M10 verbatim, issued via PSEHB/PED Notification (4 December 2024). PMDA inspectors interpret "pivotal" narrowly vs. EMA / ANVISA broader read.
RDC 742/2022.
Adopts ICH M10 by reference. Effective March 1 2023. Q1 2026 published Portuguese implementation guide.
WHO PQ + M10 cumulative.
For WHO Prequalification submissions, WHO inspectors apply both the WHO bioanalytical PQ standard and ICH M10. Stricter prevails. Specific WHO Technical Report Series annex citation to be confirmed against current WHO PQ guidance.
ISR sample selection.
~28% of bioanalytical 483 observations iFeed reviewed in 2025 · randomisation defensibility, concentration-range coverage, time-point distribution. The most-cited finding of the year. Source: iFeed analysis of public 483s and Warning Letters; FDA does not publish category-level breakdowns.
Reagent-lot bridging.
~22% of observations reviewed. Documentation of critical-reagent transitions: which lot validated when, which lot ran which study sample, what bridging experiment closed the gap.
Partial-validation SOP gaps.
~17%. Pre-defined triggers and acceptance criteria for partial revalidation events (matrix change, anticoagulant change, site transfer, reagent change).
Method-transfer documentation.
~14%. Sponsor → CRO and CRO → CRO transfer evidence. PMDA 2024 framework cited explicitly.
QMSR bridge.
QMSR effective Feb 2 2026 forced documented handshake: intended use (design input), risk assessment 820.30(g), change control 820.30(i). Sponsors with pre-QMSR files must retrofit.
EMA Reflection Paper 2026.
EMA ATMP Reflection Paper · drafting begins under CAT 2026 workplan; public consultation expected later. FDA case-by-case. PMDA silent. ANVISA defers to EMA.